NatureSelect.ai Secures Over $100M; Aulis Capital Launches First Fund

Substantial Funding for NatureSelect.ai

NatureSelect.ai, a promising Shenzhen-based startup focusing on AI-driven emotional companionship, has successfully raised over $100 million in a recent financing round. This funding aligns with the company’s preparations for launching its innovative product this month.

The investment has garnered attention from several reputable firms, including 5Y Capital, Qiming Venture Partners, SCV, iMPC, and HyT Capital.

Innovations in AI Emotional Companionship

Founded in early 2024, NatureSelect.ai sets out to foster lasting relationships between humans and AI through its cutting-edge products. Central to its offerings is EVE, a sophisticated 3D AI companion with advanced long-term memory. EVE not only engages users through text, voice, and video but also takes initiative in performing real-life tasks—be it ordering bubble tea or arranging flower deliveries, thereby seamlessly integrating into users’ daily routines.

In addition, NatureSelect.ai is developing Elys, an agentic social network that captures and builds contextual memories through user interactions. This platform aims to create personalized AI avatars that assist users in discovering valuable insights and fostering meaningful connections, creating a rich tapestry of experiences within the network.

Having initiated a private beta for Elys earlier this year, the company has been diligently working on enhancing its multi-user social memory system, with a strong emphasis on privacy protection and connectivity improvements. The updated version of Elys is currently available through invite-only beta testing, with a full release anticipated later this month.

Aulis Capital's Ambitious Launch

Meanwhile, Aulis Capital, an investment firm launched by former Qiming managing partner Nisa Leung, has successfully closed its inaugural fund, Aulis Capital Fund I, L.P., which has accrued a total of $200 million in commitments. Established in October 2025, Aulis Capital centers its investments on early- to growth-stage companies within the life sciences and healthcare sectors.

Leung expressed her conviction regarding the synergy between biopharma and disciplined capital in a recent LinkedIn post, stating, “The intersection of biopharma and capital discipline holds the key to transforming global health outcomes.” With Aulis Fund I, she aims to reinforce this thesis by aligning with top-tier operators, investors, and innovators to reshape the future of medicine.

Focus on Health Innovation

Aulis Capital operates from strategic locations, including Hong Kong, Beijing, Shanghai, Silicon Valley, and Boston, all aimed at empowering startups that push the envelope in drug development and digital, AI-converging healthcare solutions. Notably, the firm announced its involvement in a $107 million Series B funding round for EpiBiologics, a US-based company dedicated to next-generation protein degradation systems targeting extracellular membrane and soluble proteins.

The formation of Aulis Capital heralds a fresh chapter for Leung, who left Qiming in February 2025 after nearly two decades of influential work, notably establishing their healthcare investment practice. There, she orchestrated investments in significant companies such as Gan & Lee Pharmaceuticals, Zai Lab, CanSino Biologics, and Insilico Medicine, shaping the medical investment landscape.